Deuterium depletion inhibits lung cancer cell growth and migration in vitro and results in severalfold increase of median survival time of non-small cell lung cancer patients receiving conventional therapy

Non-small cell lung cancer (NSCLC) is the most common type of cancer, accounting for 84% all diagnoses. In advanced NSCLC, including adenocarcinoma and squamous carcinoma, median survival time (MST) rarely exceeds 10-12 months. Reduced deuterium (D) concentration in water tissue culture media drinking humans has shown a strong anticancer effect previous investigations. present study, 1 parts per million (ppm) decrease D-concentration every 8 hours resulted reduced growth rate A459 line vitro, migration was also dose-dependently reduced. Retrospective study 183 NSCLC patients consuming commercially available deuterium-depleted (DDW) revealed severalfold increase MST, which 149 months 19 40 110 patients, who started DDW-consumption at early or stage, respectively. Interestingly, MST showed significant difference by gender (107 females 41.2 males). Application DDW combination with surgery plus other conventional therapies (68 patients) gave while combined chemotherapy only (48 43.7 The results support earlier data that integration D-depletion to increases efficacy therapy, reduces relapse MST.